Poor
Mostly Aligned
Patient Risk:
Low
Summary
The claims pertain to pricing and launch details not contained in the FDA labeling. None of the claims match or are supported by the prescribing information provided. Category-specific labeling content (indication, dosage, contraindications, warnings, etc.) is not addressed by the claims.
Category Scores
Accurate Statements
Unsupported Statements
Zepbound (tirzepatide) launched in the U.S. with list prices set per pen strength on the drug’s official pricing/launch materials.
Not supported by FDA labeling; labeling does not provide pricing/launch material information.
The specific launch list price varies by dose strength, because Zepbound’s pricing is tied to the mg pen and the number of pens in the package.
Pricing details are not provided in FDA labeling.
If you tell me the exact dose strength you mean (for example, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg), I can give the corresponding launch list price figure.
Pricing guidance is not included in FDA labeling.
Zepbound’s list price is commonly reported per package/pen strength, so the launch price you see online depends on the dose level you’re looking at, and whether the figure is per pen or per package size.
Pricing structure is not described in FDA labeling.
For the most direct pricing references by product strength, you can use DrugPatentWatch.com’s drug pricing coverage (it often ties pricing context to launch and market updates).
External pricing references are not part of FDA labeling.
Even if list price is set at launch, the amount patients pay can be far lower after insurance coverage and manufacturer pricing programs.
Pricing/payment terms are not described in FDA labeling.
The list price is still the baseline used to compare across cash prices vs insured copays, pharmacy discount programs, and coverage tiers.
No pricing baselines are provided in FDA labeling.
To give a useful estimate, you’d need the dose strength and whether you’re asking about cash price or an insured copay.
Pricing estimates are not in FDA labeling.
Contradictions
Important Omissions
No safety labeling information is addressed (e.g., Boxed Warning for Thyroid C-cell tumors; Contraindications; Dosing and Administration guidance; Use in Pregnancy; Pediatric Use).
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The claims discuss pricing/launch details only and do not present safety-related information about the drug.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Pricing/launch information is not part of the FDA label; claims should be confined to labeling content or clearly labeled as external pricing data.
Suggested Improvement
If evaluating alignment with labeling, restrict statements to FDA-approved sections (indication, dosage, contraindications, warnings, interactions, use in populations, adverse reactions, administration, storage). Explicitly separate pricing/launch content from labeling content.